Status:
ACTIVE_NOT_RECRUITING
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Primary Central Nervous System Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
Eligibility Criteria
Inclusion
- Patients diagnosed with PCNSL
- Patients who have not received treatment for PCNSL in the past
- Patients with ECOG Performance Status 0-2
- Patients expected to survive for 6 months or more
Exclusion
- Patients with intraocular PCNSL without brain lesions
- Patients are unable to swallow oral medications
Key Trial Info
Start Date :
May 17 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06541665
Start Date
May 17 2024
End Date
August 31 2028
Last Update
June 3 2025
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
2
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
3
Akita University Hospital
Akita, Akita, Japan
4
Juntendo University Urayasu Hospital
Urayasu-shi, Chiba, Japan